Clinical trials: Covid19
COVID-19
Intestinal Microbiota of Patients Hospitalized With Sars-CoV-2
The study investigators hypothesize that SARS-Cov2 infection alters the composition of the digestive microbiota and its functionality, resulting in changes in intestinal permeability and consequently in microbial digestive…
- Trial name
- MICRODIGCOV (NCT05178238)
- Testing
- Fecal sample
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Gastrointestinal Post Acute COVID-19 Syndrome
The Clinical Significance of Gut Permeability in Gastrointestinal Post Acute COVID-19 Syndrome
Severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) and the associated coronavirus disease 2019 (COVID-19) have been spreading all around the world for past 3 years.
- Trial name
- NCT05612087
- Testing
- Confocal laser endomicroscopy
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Pulse Steroid and Immunoglobulins Drugs in Covid 19 Patients
Combined Use of Immunoglobulin and Pulse Steroid Therapies in Severe Covid-19 Patients
In December 2019, SARS-COV-2 was isolated from patients for the first time . It then rapidly turned into a pandemic affecting the whole world.While most Covid patients survive the disease with mild symptoms, some may develop…
- Trial name
- NCT06223984
- Testing
- pulse steroid and nanogam
- Where
- Turkey (Türkiye)
- Volunteers
- 178 people
- Sponsor
- Konya City Hospital
Covid19
Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)
The current research is a pilot study to determine the feasibility of recruiting and retaining 40 participants diagnosed with COVID-19.
- Trial name
- NCT04570449
- Testing
- Fluoxetine
- Where
- United States
- Sponsor
- Milton S. Hershey Medical Center
COVID
Niclosamide In Moderate COVID-19
This is a Phase 2, multicentre, randomized, double blind, 2 arm placebo-controlled study in adults with moderate COVID-19 with gastrointestinal signs and symptoms.
- Trial name
- NCT04436458
- Testing
- Niclosamide Oral Tablet
- Sponsor
- Entero Therapeutics
Coronavirus Infections
Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial
Coronavirus disease 2019 (COVID-19) was recognized as a pandemic on March 11, 2020 by the World Health Organization. The virus that causes COVID-19 (SARS-CoV-2) is easily transmitted through person to person and there is still no…
- Trial name
- NCT04327349
- Testing
- Convalescent Plasma
- Where
- Iran
- Volunteers
- 30 people
- Sponsor
- Mazandaran University of Medical Sciences
Complement Abnormality, Peripheral Blood Mononuclear Cells
The Role of Natural Killer, Complement and T-lymphocytes in COVID-19 Disease, a Prospective Monocentric Study
The current study is an open, non-randomized, monocentric, and interventional study. CoViD-19 patients will be recruited at UZ Brussel after informed consent is obtained.
- Conditions
- Complement Abnormality, Peripheral Blood Mononuclear Cells, Covid19
- Trial name
- TONIC (NCT05258643)
- Testing
- Blood analysis
- Where
- Belgium
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
COVID-19; Cardiovascular Diseases
Cardiac complicAtions in Patients With SARS Corona vIrus 2 (COVID-19) regisTrY
CAPACITY (www.capacity-covid.eu) is a registry of patients with COVID-19 across Europe and has been established to answer questions on the role of cardiovascular disease in this pandemic.
- Trial name
- CAPACITY-COVID (NCT04325412)
- Where
- Netherlands
- Volunteers
- 1,000 people
- Sponsor
- UMC Utrecht
Covid19
Hyperpolarized 129Xe MRI of Survivors of COVID-19
The purpose of this study is to evaluate pulmonary function of patients recovering from mild, moderate, and severe COVID-19 disease using hyperpolarized 129Xe MRI.
- Trial name
- NCT04659707
- Testing
- Hyperpolarized Xe129
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Kansas Medical Center
Pulmonary Alveolar Proteinosis, COPD
Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection
COVID-19 Viral Global Pandemic resulting in post-infection pulmonary damage, including Fibrotic Lung Disease due to inflammatory and reactive protein secretions damaging pulmonary alveolar structure and functionality.
- Conditions
- Pulmonary Alveolar Proteinosis, COPD, Idiopathic Pulmonary Fibrosis, Viral Pneumonia
- Trial name
- GARM-COVID19 (NCT04326036)
- Testing
- Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF), Centricyte 1000, IV Deployment Of cSVF In Sterile Normal Saline IV Solution
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Black Tie Medical, Inc.
COVID-19
MG Granules Improve COVID-19 Efficacy and Safety of Convalescent Exercise Tolerance
The global coronavirus pandemic has infected nearly 659 million people and killed more than 6.6 million in the past three years.
- Trial name
- NCT05722093
- Testing
- Manzi Guben granules
- Volunteers
- 360 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
SARS-CoV 2, COVID-19
Test and Treat COVID 65plus+
Patients over equal or older than 65 yearswill be treated with a hydroxychloroquine versus placebo reduced loading dose of 600mg on the first day followed with 400mg/day divided in 2x200mg for 6 more days resulting in a total…
- Trial name
- COVID65plus (NCT04351516)
- Testing
- Hydroxychloroquine
- Where
- 2 sites in Germany
- Sponsor
- University Hospital Tuebingen
Drug Compliance
The Effect of Motivational Interviewing on the Adherence to Medication of Patients With COVID-19 Diagnosed at Home
Summary Objective: The aim of this study is to determine the effect of health education supported by motivational interviewing on drug therapy compliance of patients with COVID-19 who are followed at home.
- Trial name
- MOTIVATION (NCT05676021)
- Testing
- motivational interview
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Saglik Bilimleri Universitesi Gulhane Tip Fakultesi
SARS-CoV Infection, COVID-19
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
Adults who do not have major health, kidney, gastrointestinal disease will be randomized to receive oral mitoquinone/mitoquinol mesylate (Mito-MES) versus placebo to prevent the development and progression of COVID-19 after…
- Trial name
- NCT05886816
- Testing
- Mitoquinone/mitoquinol mesylate
- Where
- United States
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
COVID-19
The COVID-19 Mobile Health Study (CMHS)
This study evaluates a brand-new cell phone-based auto-diagnosis system, which is based on the clinical guidelines, clinical experience, and statistic training model.
- Trial name
- CMHS (NCT04275947)
- Testing
- nCapp, a cell phone-based auto-diagnosis system
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Chinese Alliance Against Lung Cancer
COVID-19, COVID-19 Pandemic
Community-engaged Optimization of COVID-19 Rapid Evaluation And TEsting Experiences
Throughout the Coronavirus disease (COVID-19) pandemic, rates of COVID-19 have been persistently high in San Diego County's central and southern communities near the United States/Mexico border.
- Trial name
- CO-CREATE-Ex (NCT05894655)
- Testing
- COVID-19 walk-up, on-site testing strategy, Community Health Worker (CHW) leading testing navigation and general preventive care reminders, No-cost self-testing kit vending machines
- Where
- United States
- Volunteers
- 6,527 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
COVID-19 Infection, COVID-19 VACCINE
Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine
This prospective, multi-center, randomized, observer-blind Phase 2 study. A total of 1320 participants will be divided into 2 groups (660 each) receiving either full dose or half dose of either AZ or PF.
- Trial name
- NCT05049226
- Testing
- AstraZeneca ChAdOx1 AZD1222 vaccine (AZ) full dose, Pfizer/BioNTech BNT162b2 vaccine (PF) full dose, AstraZeneca ChAdOx1 AZD1222 vaccine (AZ) half dose
- Where
- 7 sites in Thailand
- Volunteers
- 1,250 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Coronavirus, Coronavirus Infection
Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study
Convalescent plasma (CP) has been used in recent years as an empirical treatment strategy when there is no vaccine or treatment available for infectious diseases.
- Trial name
- CP-COVID-19 (NCT04332835)
- Testing
- Plasma, Standard Therapy
- Where
- Colombia
- Volunteers
- 92 people
- Sponsor
- Universidad del Rosario
COVID-19
Administration of Chlorpromazine as a Treatment for COVID-19
In this study, defined cases of COVID-19 confirmed with PCR, with a mild, moderate or severe pneumonia will be treated with chlorpromazine.
- Trial name
- NCT04354805
- Testing
- Chlorpromazine
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Cairo University
COVID-19
A Randomized Controlled Trial of a Digital, Self-testing Strategy for COVID-19 Infection in South Africa.
As the world opens up to rapidly increasing vaccination coverage and newer variants, there is an even greater need for timely access to at-home COVID-19 testing, or self-testing based out of kiosks, offices, or private spaces.
- Trial name
- NCT05436795
- Testing
- Abbott Panbio rapid antigen self-tests, COVIDSmart CARE! app
- Where
- South Africa
- Volunteers
- 600 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre